Trial Profile
Phase I and II, open-label, multi-center trials of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Lapatinib
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline Research & Development; GSK
- 01 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 01 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 01 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.